Hemington Wealth Management Makes New Investment in Danaher Co. (NYSE:DHR)

Hemington Wealth Management purchased a new stake in Danaher Co. (NYSE:DHR) in the 1st quarter, Holdings Channel reports. The fund purchased 863 shares of the conglomerate’s stock, valued at approximately $216,000.

A number of other institutional investors have also recently modified their holdings of the business. ST Germain D J Co. Inc. grew its holdings in Danaher by 1.4% during the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after buying an additional 41 shares during the last quarter. Godsey & Gibb Inc. grew its holdings in Danaher by 3.0% during the 1st quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after buying an additional 42 shares during the last quarter. Nicholas Hoffman & Company LLC. grew its holdings in Danaher by 2.3% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after buying an additional 43 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in Danaher by 1.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after buying an additional 43 shares during the last quarter. Finally, Berger Financial Group Inc grew its holdings in Danaher by 1.7% during the 4th quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after buying an additional 43 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Up 1.7 %

Shares of DHR traded up $4.07 during trading hours on Thursday, hitting $246.27. The stock had a trading volume of 2,793,164 shares, compared to its average volume of 2,861,634. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The firm has a market cap of $182.41 billion, a P/E ratio of 41.74, a P/E/G ratio of 3.68 and a beta of 0.83. The company’s fifty day simple moving average is $255.06 and its 200 day simple moving average is $247.32. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $269.11.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period last year, the company posted $2.36 EPS. The business’s quarterly revenue was down 2.6% on a year-over-year basis. Equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on DHR shares. TD Cowen increased their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price target on the stock. Barclays increased their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Evercore ISI reduced their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Finally, Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $268.67.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Insiders have sold 148,783 shares of company stock valued at $37,536,717 over the last three months. 10.90% of the stock is owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.